February 19, 2019 / Last updated : February 19, 2019 Benjamin Clark Pharmaceuticals

Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

February 15, 2019 / Last updated : February 15, 2019 Benjamin Clark Pharmaceuticals

Alexion Pharmaceuticals Inc Valuation – February 2019 $ALXN

Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.

February 13, 2019 / Last updated : February 13, 2019 Benjamin Clark Pharmaceuticals

Vertex Pharmaceuticals Inc Valuation – February 2019 $VRTX

Vertex Pharmaceuticals Incorporated does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

February 5, 2019 / Last updated : February 5, 2019 Benjamin Clark Pharmaceuticals

Perrigo Company Valuation – February 2019 $PRGO

Perrigo Company PLC does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios.

January 23, 2019 / Last updated : January 23, 2019 Benjamin Clark Pharmaceuticals

Eli Lilly and Co Valuation – January 2019 $LLY

Eli Lilly And Co does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios.

January 10, 2019 / Last updated : January 10, 2019 Benjamin Clark Pharmaceuticals

Zoetis Inc Valuation – January 2019 $ZTS

Zoetis Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

January 4, 2019 / Last updated : January 4, 2019 Benjamin Clark Pharmaceuticals

Gilead Sciences Inc Valuation – January 2019 $GILD

Gilead Sciences, Inc. qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.

November 20, 2018 / Last updated : November 20, 2018 Benjamin Clark Pharmaceuticals

Pfizer Inc Valuation – November 2018 $PFE

Pfizer Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PEmg and PB ratios.

November 20, 2018 / Last updated : November 20, 2018 Benjamin Clark Pharmaceuticals

Nektar Therapeutics Valuation – November 2018 $NKTR

Nektar Therapeutics does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

November 17, 2018 / Last updated : November 18, 2018 Benjamin Clark Pharmaceuticals

Merck & Co Inc Valuation – November 2018 $MRK

Merck & Co., Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.